600 MHz NMR Spectrometer for Solution-state NMR

描述(由申请人提供)：申请资助一台600-MHz核磁共振光谱仪，以满足NIH用户组的解决方案状态核磁共振需求，该用户组由加州大学伯克利分校化学系的七名资深教员组成，他们总共得到了20项NIH主要拨款的资助。新仪器将取代过时的500 MHz分光计(即Bruker DRX-500，由牛津仪器公司已有22年历史的磁铁和10年前的电子控制台组成)。NIH用户组的核磁共振需求需要600 MHz磁铁提供的灵敏度和分辨率。新仪器必须适应NIH用户组广泛的核磁共振应用，需要至少两种不同的探头，即用于依赖高灵敏度1H检测的实验的三共振宽带反向探头和用于高灵敏度直接检测13C和除1H以外的各种核的宽带观察探头。600兆赫的核磁共振将极大地加速由10个教员(7个主要用户和3个次要用户)组成的研究小组进行的科学研究，资金来自24个不同的NIH拨款。这项研究对人类健康具有明显而重大的影响，包括新治疗靶点的发现和表征，作为治疗人类严重疾病药物开发的起始化合物的小分子配体的设计和合成，药物和疫苗纳米递送载体的开发，以及用于疾病诊断和预后的新的敏感化学传感方法的开发，如第二代核磁共振试剂。

DESCRIPTION (provided by applicant): Funding is requested for a 600-MHz NMR spectrometer to accommodate the solution state NMR needs of the NIH User Group comprised of seven established faculty in the UC Berkeley Department of Chemistry who in aggregate are funded by 20 major NIH grants. The new instrument will replace an outdated 500-MHz spectrometer (namely, a Bruker DRX-500, comprised of a 22-year old Oxford Instruments magnet and 10-year old electronics console). The NMR needs of the NIH User Group require the sensitivity and resolution provided by a 600-MHz magnet. The new instrument must accommodate the NIH User Group's broad range of NMR applications, calling for at least two different probes, namely, a triple-resonance broadband inverse probe for experiments that depend on high-sensitivity 1H detection and a broadband-observe probe for high-sensitivity direct detection of 13C and a variety of nuclei other than 1H. The 600-MHz NMR will greatly accelerate the science carried out by the research groups of ten faculty (seven major and three minor users) with funding from 24 distinct NIH grants. This research has clear, significant impact on human health, including the discovery and characterization of new therapeutic targets, the design and synthesis of small molecule ligands as the starting compounds for the development of drugs to treat serious human diseases, the development of nano-based delivery vehicles for drugs and vaccines, and the development of new sensitive chemical sensing methods for disease diagnosis and prognosis such as second generation MRI agents.